{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:05:35Z","timestamp":1747181135164,"version":"3.40.5"},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"41","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,13]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>A chronic autoimmune liver disease known as primary biliary cholangitis (PBC) that selectively destructs small intrahepatic biliary epithelial cells and may result in biliary cirrhosis and eventually liver transplantation or death. PBC is associated with various other extrahepatic autoimmune diseases; however, the combination of PBC with ankylosing spondylitis has been rarely reported in the literature. Here, we reported a case of PBC with ankylosing spondylitis to improve our understanding of such coexistence and provide new ideas for the treatment of such patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 54-year-old man was presented to the Department of Rheumatology because of an abnormal liver function test for 7 years, chest and back pain for 1 year, and low back pain for 2 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Primary biliary cholangitis, ankylosing spondylitis, and old pulmonary tuberculosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient refused to use nonsteroidal anti-inflammatory drugs, conventional synthetic disease-modifying antirheumatic drugs, and biologic disease-modifying antirheumatic drugs; thus, he was treated with methylenediphosphonate (99Tc-MDP) and ursodeoxycholic acid (UDCA).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The patient achieved remission with UDCA and 99Tc-MDP therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>In the treatment of PBC combined with other disorders, the characteristics of different diseases should be considered. The patient reported herein was treated with 99Tc-MDP and UDCA, and his condition improved; thus, we consider 99Tc-MDP to be an effective treatment. Furthermore, in line with the current understanding of the pathogenesis of PBC and ankylosing spondylitis, we hypothesize that interleukin-17 inhibitor is an effective treatment for such patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000035655","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T21:02:15Z","timestamp":1697230935000},"page":"e35655","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["A case report of primary biliary cholangitis combined with ankylosing spondylitis"],"prefix":"10.1097","volume":"102","author":[{"given":"Chunfeng","family":"Hou","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Jining No.1 People\u2019s Hospital, Jining, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunfeng","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Jining No.1 People\u2019s Hospital, Jining, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luan","family":"Luan","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Jining No.1 People\u2019s Hospital, Jining, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3542-2150","authenticated-orcid":false,"given":"Shujie","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Jining No.1 People\u2019s Hospital, Jining, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"Suppl 1","key":"R1-20250504","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/liv.14378","article-title":"The future of autoimmune liver diseases - understanding pathogenesis and improving morbidity and mortality.","volume":"40","author":"Engel","year":"2020","journal-title":"Liver Int"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1055\/s-0039-1697617","article-title":"The pathogenesis of primary biliary cholangitis: a comprehensive review.","volume":"40","author":"Lleo","year":"2020","journal-title":"Semin Liver Dis"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMra043898","article-title":"Primary biliary cirrhosis.","volume":"353","author":"Kaplan","year":"2005","journal-title":"N Engl J Med"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/cmi.2009.104","article-title":"Experimental evidence on the immunopathogenesis of primary biliary cirrhosis.","volume":"7","author":"Selmi","year":"2010","journal-title":"Cell Mol Immunol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.autrev.2008.06.009","article-title":"Is autoimmunity a matter of sex?","volume":"7","author":"Lleo","year":"2008","journal-title":"Autoimmun Rev"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1053\/gast.2002.36027","article-title":"Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years.","volume":"123","author":"Prince","year":"2002","journal-title":"Gastroenterology"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"102328","DOI":"10.1016\/j.jaut.2019.102328","article-title":"The challenges of primary biliary cholangitis: what is new and what needs to be done.","volume":"105","author":"Terziroli Beretta-Piccoli","year":"2019","journal-title":"J Autoimmun"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1042\/CS20181123","article-title":"Immunological abnormalities in patients with primary biliary cholangitis.","volume":"133","author":"Ma","year":"2019","journal-title":"Clin Sci (Lond)"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(15)00154-3","article-title":"Primary biliary cirrhosis.","volume":"386","author":"Carey","year":"2015","journal-title":"Lancet (Lond, Eng)"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jaut.2015.07.004","article-title":"The immunogenetics of primary biliary cirrhosis: a comprehensive review.","volume":"64","author":"Webb","year":"2015","journal-title":"J Autoimmun"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev-pathol-020712-164014","article-title":"The immunobiology and pathophysiology of primary biliary cirrhosis.","volume":"8","author":"Hirschfield","year":"2013","journal-title":"Annu Rev Pathol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/jgh.15214","article-title":"Extrahepatic autoimmune diseases in primary biliary cholangitis: prevalence and significance for clinical presentation and disease outcome.","volume":"36","author":"Efe","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","article-title":"Ankylosing spondylitis.","volume":"369","author":"Braun","year":"2007","journal-title":"Lancet (Lond, Eng)"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13075-016-1027-9","article-title":"The prevalence and clinical characteristics of nonradiographic axial spondyloarthritis among patients with inflammatory back pain in rheumatology practices: a multinational, multicenter study.","volume":"18","author":"Burgos-Varga","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00004836-199404000-00032","article-title":"Primary biliary cirrhosis associated with ankylosing spondylitis.","volume":"18","author":"Vargas","year":"1994","journal-title":"J Clin Gastroenterol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4166\/kjg.2022.048","article-title":"Primary biliary cholangitis with ankylosing spondylitis.","volume":"79","author":"Hong","year":"2022","journal-title":"Korean J Gastroenterol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/17843286.2017.1290567","article-title":"Successful infliximab therapy in a patient with comorbid spondyloarthritis, primary biliary cirrhosis and generalized morphea.","volume":"72","author":"Resorlu","year":"2017","journal-title":"Acta Clin Belg"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"3073504","DOI":"10.1155\/2017\/3073504","article-title":"Genetic contribution to the pathogenesis of primary biliary cholangitis.","volume":"2017","author":"Joshita","year":"2017","journal-title":"J Immunol Res"},{"key":"R19-20250504","first-page":"1","article-title":"Primary biliary cirrhosis.","volume":"61","author":"Dauphinee","year":"1949","journal-title":"Can Med Assoc J"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/j.clinre.2015.08.001","article-title":"Changing nomenclature for PBC: from \u201ccirrhosis\u201d to \u201ccholangitis\u201d.","volume":"39","author":"Beuers","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(20)31607-X","article-title":"Primary biliary cholangitis.","volume":"396","author":"Lleo","year":"2020","journal-title":"Lancet (Lond, Eng)"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/ng.627","article-title":"Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis.","volume":"42","author":"Liu","year":"2010","journal-title":"Nat Genet"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1053\/j.gastro.2004.05.005","article-title":"Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment.","volume":"127","author":"Selmi","year":"2004","journal-title":"Gastroenterology"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/ng.789","article-title":"Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis.","volume":"43","author":"Mells","year":"2011","journal-title":"Nat Genet"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"14828","DOI":"10.1038\/ncomms14828","article-title":"A genome-wide association study identifies six novel risk loci for primary biliary cholangitis.","volume":"8","author":"Qiu","year":"2017","journal-title":"Nat Commun"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jhep.2003.11.033","article-title":"Primary biliary cirrhosis: an infectious disease caused by chlamydia pneumoniae?","volume":"40","author":"Abdulkarim","year":"2004","journal-title":"J Hepatol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0168-8278(00)80003-3","article-title":"Antibodies against the COOH-terminal region of E. coli ClpP protease in patients with primary biliary cirrhosis.","volume":"33","author":"Mayo","year":"2000","journal-title":"J Hepatol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/hep.23783","article-title":"Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis.","volume":"52","author":"Lleo","year":"2010","journal-title":"Hepatology"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/hep.27840","article-title":"The biliary epithelium presents antigens to and activates natural killer T cells.","volume":"62","author":"Schrumpf","year":"2015","journal-title":"Hepatology"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.4049\/jimmunol.1600096","article-title":"Clonal characteristics of circulating B lymphocyte repertoire in primary biliary cholangitis.","volume":"197","author":"Tan","year":"2016","journal-title":"J Immunol"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1002\/hep.26979","article-title":"IL-12\/Th1 and IL-23\/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy.","volume":"59","author":"Yang","year":"2014","journal-title":"Hepatology"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1002\/hep.28122","article-title":"Natural killer cells regulate T cell immune responses in primary biliary cirrhosis.","volume":"62","author":"Shimoda","year":"2015","journal-title":"Hepatology"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jaut.2016.12.012","article-title":"Chemokine receptor CXCR3 deficiency exacerbates murine autoimmune cholangitis by promoting pathogenic CD8(+) T cell activation.","volume":"78","author":"Ma","year":"2017","journal-title":"J Autoimmun"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2017.12.007","article-title":"A cellular and molecular view of T helper 17 cell plasticity in autoimmunity.","volume":"87","author":"Stadhouders","year":"2018","journal-title":"J Autoimmun"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jaut.2008.11.001","article-title":"Hepatic IL-17 responses in human and murine primary biliary cirrhosis.","volume":"32","author":"Lan","year":"2009","journal-title":"J Autoimmun"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"e1888","DOI":"10.1097\/MD.0000000000001888","article-title":"The distribution and the fibrotic role of elevated inflammatory Th17 Cells in patients with primary biliary cirrhosis.","volume":"94","author":"Shi","year":"2015","journal-title":"Medicine (Baltim)"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.cyto.2013.07.005","article-title":"Increased IL-23 and IL-17 expression by peripheral blood cells of patients with primary biliary cirrhosis.","volume":"64","author":"Qian","year":"2013","journal-title":"Cytokine"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s10875-009-9328-2","article-title":"Implication of Th17 and Th1 cells in patients with chronic active hepatitis B.","volume":"30","author":"Ge","year":"2010","journal-title":"J Clin Immunol"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"389","DOI":"10.21037\/atm.2019.07.100","article-title":"The expression and clinical significance of serum IL-17 in patients with primary biliary cirrhosis.","volume":"7","author":"Sun","year":"2019","journal-title":"Ann Transl Med"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis.","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0168-8278(01)00092-7","article-title":"Ursodeoxycholic acid \u201cmechanisms of action and clinical use in hepatobiliary disorders.\u201d.","volume":"35","author":"Lazaridis","year":"2001","journal-title":"J Hepatol"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"111754","DOI":"10.1016\/j.biopha.2021.111754","article-title":"The pathogenesis, models and therapeutic advances of primary biliary cholangitis.","volume":"140","author":"Li","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/hep.1840110504","article-title":"Sj\u00f6gren\u2019s syndrome in patients with primary biliary cirrhosis.","volume":"11","author":"Tsianos","year":"1990","journal-title":"Hepatology"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s12016-015-8471-1","article-title":"The coexistence of Sj\u00f6gren\u2019s syndrome and primary biliary cirrhosis: a comprehensive review.","volume":"48","author":"Sun","year":"2015","journal-title":"Clin Rev Allergy Immunol"},{"key":"R45-20250504","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jaut.2009.09.006","article-title":"Clustering and commonalities among autoimmune diseases.","volume":"33","author":"Mackay","year":"2009","journal-title":"J Autoimmun"},{"key":"R46-20250504","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/hep.20907","article-title":"Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients.","volume":"42","author":"Gershwin","year":"2005","journal-title":"Hepatology"},{"key":"R47-20250504","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jaut.2011.11.005","article-title":"Primary biliary cirrhosis and Sj\u00f6gren\u2019s syndrome: autoimmune epithelitis.","volume":"39","author":"Selmi","year":"2012","journal-title":"J Autoimmun"},{"key":"R48-20250504","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1572-0241.1998.00404.x","article-title":"Gluten sensitivity in patients with primary biliary cirrhosis.","volume":"93","author":"Niveloni","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"R49-20250504","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/gut.42.1.120","article-title":"The association between primary biliary cirrhosis and coeliac disease: a study of relative prevalences.","volume":"42","author":"Kingham","year":"1998","journal-title":"Gut"},{"key":"R50-20250504","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41584-021-00625-y","article-title":"Ankylosing spondylitis: an autoimmune or autoinflammatory disease?","volume":"17","author":"Mauro","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"R51-20250504","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/1756-185X.13679","article-title":"Clinical practice recommendations for the use of imaging in the diagnosis and management of axial spondyloarthritis in Taiwan.","volume":"23","author":"Wei","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"R52-20250504","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1002\/art.24968","article-title":"Identification of RGS1 as a candidate biomarker for undifferentiated spondylarthritis by genome-wide expression profiling and real-time polymerase chain reaction.","volume":"60","author":"Gu","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R53-20250504","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1002\/art.1780401015","article-title":"Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment.","volume":"40","author":"Brown","year":"1997","journal-title":"Arthritis Rheum"},{"key":"R54-20250504","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1093\/rheumatology\/ker211","article-title":"Effects of genetic polymorphisms of programmed cell death 1 and its ligands on the development of ankylosing spondylitis.","volume":"50","author":"Huang","year":"2011","journal-title":"Rheumatology (Oxford, England)"},{"key":"R55-20250504","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.3899\/jrheum.130515","article-title":"Higher expression of whole blood microRNA-21 in patients with ankylosing spondylitis associated with programmed cell death 4 mRNA expression and collagen cross-linked C-telopeptide concentration.","volume":"41","author":"Huang","year":"2014","journal-title":"J Rheumatol"},{"key":"R56-20250504","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000484250","article-title":"The impact of anti-TNF therapy on CD4+ and CD8+ cell subsets in ankylosing spondylitis.","volume":"85","author":"Dulic","year":"2018","journal-title":"Pathobiology"},{"key":"R57-20250504","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/BOR.0000000000000069","article-title":"The interleukin-23\/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis.","volume":"26","author":"Yeremenko","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"R58-20250504","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","article-title":"Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16-week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"R59-20250504","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10067-010-1647-4","article-title":"Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis.","volume":"30","author":"Mei","year":"2011","journal-title":"Clin Rheumatol"},{"key":"R60-20250504","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1186\/ar3370","article-title":"Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response.","volume":"13","author":"Appel","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"R61-20250504","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/art.33507","article-title":"Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive \u03b3\/\u03b4 T cells in patients with active ankylosing spondylitis.","volume":"64","author":"Kenna","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R62-20250504","doi-asserted-by":"crossref","first-page":"e31000","DOI":"10.1371\/journal.pone.0031000","article-title":"Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis.","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"key":"R63-20250504","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1053\/j.gastro.2012.07.031","article-title":"Th17 cells regulate liver fibrosis by targeting multiple cell types: many birds with one stone.","volume":"143","author":"Gao","year":"2012","journal-title":"Gastroenterology"},{"key":"R64-20250504","first-page":"396","article-title":"Effects and safety of 99Tc-MDP in patients with refractory ankylosing spondylitis: a 2-stage (30-week follow-up) clinical trial.","volume":"36","author":"Xu","year":"2018","journal-title":"Clin Exp Rheumatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035655","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:13:03Z","timestamp":1746324783000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":64,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000035655","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2023,10,13]]}}}